Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ODC1 | P11926 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7201462 | 1.00 | ODC1 (0.34) | ODC1KDM4ELMNAMAPTRAB9A | |
| SCHEMBL7198481 | 0.83 | CYP1A2 (0.42) | ODC1KDM4ELMNAMAPTRAB9A | |
| SCHEMBL7198486 | 0.83 | CYP1A2 (0.42) | ODC1KDM4ELMNAMAPTRAB9A | |
| SCHEMBL11404255 | 0.83 | TSHR (0.45) | KDM4ELMNA | |
| SCHEMBL11476306 | 0.81 | — | — | |
| SCHEMBL7204475 | 0.80 | GRM4 (0.31) | — | |
| SCHEMBL11410701 | 0.79 | TSHR (0.41) | KDM4ELMNAMAPTSMN1; SMN2 | |
| SCHEMBL4813122 | 0.77 | ODC1 (0.47) | ODC1KDM4ELMNAMAPTRAB9A | |
| SCHEMBL4813114 | 0.77 | ODC1 (0.47) | ODC1KDM4ELMNAMAPTRAB9A | |
| SCHEMBL4813109 | 0.77 | ODC1 (0.47) | ODC1KDM4ELMNAMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6602910-B2 | Treating cancer in a patient comprising administering an effective amount of substantially purified D enantiomer of difluoromethylornithine | ILEX ONCOLOGY, INC. | 2003-08-05 | — | — | US | disclosed |
| US-20020045663-A1 | D-enantiomer of DFMO and methods of use therefor | ILEX ONCOLOGY, INC. (US) | 2002-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045663-A1 | D-enantiomer of DFMO and methods of use therefor | DHODH, DDT, HADHB | ODC1 34/4885KDM4E 2664/4885LMNA 3450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.